IND Swift Limited

Ind-Swift Limited, established in 1986, is a Chandigarh-based pharmaceutical company specializing in the development and export of finished pharmaceutical formulations. The company was founded by three visionaries: the Mehtas, the Munjals, and the Jains, who aimed to create a global enterprise rooted in ethical practices. Ind-Swift Limited is a privately held entity, with a promoter holding of 55.58% and public holding of 44.42% as of 2024. The company is listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) under the ticker symbols BSE:524652 and NSE:INDSWFTLTD, respectively. As of August 13, 2025, the company's stock price was ₹15.76. Ind-Swift Limited employs approximately 1,054 individuals. The company's official website is www.indswiftltd.com.

Ind-Swift Limited operates multiple state-of-the-art manufacturing facilities across India, adhering to international quality standards. These facilities are designed to produce a wide range of pharmaceutical dosage forms, including tablets, capsules, syrups, and injections. The company's manufacturing plants are strategically located in regions such as Jammu & Kashmir, Himachal Pradesh, and Punjab, enabling efficient distribution and export operations. The facilities are built according to current guidelines of MHRA, EU, WHO, and accreditations with ISO 14000.

The leadership team at Ind-Swift Limited is spearheaded by Chairman and Managing Director NR Munjal, who has been instrumental in the company's growth and strategic direction. The Joint Managing Director is Himanshu Jain, contributing significantly to the company's operations and expansion initiatives. Other key executives include Directors Sahil Munjal and Rishav Mehta, who play pivotal roles in overseeing various aspects of the company's business operations.

Ind-Swift Limited has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have received approvals from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Australia's Therapeutic Goods Administration (TGA), facilitating market access in these regions. Additionally, Ind-Swift Limited has been involved in exporting its products to Europe, Australia, Canada, South Africa, and Russia, indicating a broad international footprint.

Ind-Swift Limited has made strategic inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's Global Business Unit (GBU) has received regulatory approvals from the Ministry of Health in the UAE, GCC, and ANVISA in Brazil, enabling market access in these regions. Furthermore, the company's products are available in more than 30 countries worldwide, spanning regions such as the EU, Australia, Central & Latin America, Asia, CIS, and Africa.

Ind-Swift Limited's geographic strategy demonstrates a balanced approach to market diversification. The company's significant export value of $36.7 million USD across 1,476 shipments to 13 products in 9 therapeutic categories indicates a well-distributed market presence. The top three therapeutic categories—Antihistamines & Allergy (51.5%), Cardiovascular (22.1%), and Antibiotics (7.8%)—reflect a strategic focus on high-demand segments. The company's leadership in the Sulfasalazine market further underscores its targeted approach to market penetration. This diversified geographic footprint mitigates concentration risk and positions Ind-Swift Limited for sustained growth in various international markets.

Ind-Swift Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), allowing the company to export its pharmaceutical formulations to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for several products, facilitating market entry. Additionally, Ind-Swift Limited has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, ensuring compliance with Good Manufacturing Practices (GMP) and maintaining a positive inspection history.

Ind-Swift Limited's commitment to quality is evidenced by its adherence to international standards. The company's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practices (WHO GMP), ensuring the production of safe and effective pharmaceutical products. Additionally, the company holds European Union Good Manufacturing Practice (EU GMP) certificates, facilitating market access in EU member countries. These certifications underscore Ind-Swift Limited's dedication to maintaining high-quality manufacturing processes.

Ind-Swift Limited operates in compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations in India. The company's manufacturing facilities hold licenses issued by the CDSCO, authorizing the production of pharmaceutical formulations. State drug controller approvals further validate the company's adherence to regional regulatory standards. The company has obtained export No Objection Certificates (NOCs), permitting the export of its products to various international markets. These regulatory approvals reflect Ind-Swift Limited's commitment to maintaining high standards in manufacturing and export operations.

As of March 28, 2026, there are no publicly available records indicating that Ind-Swift Limited has received Form 483 observations, warning letters, or import alerts from regulatory authorities. This absence suggests that the company maintains a positive compliance record with regulatory agencies.

Ind-Swift Limited operates in a competitive pharmaceutical industry, with several key players in overlapping therapeutic categories. While specific market share data for competitors is not available, Ind-Swift Limited's export value of $36.7 million USD and its leadership in the Sulfasalazine market position it as a significant entity in the global pharmaceutical export sector. The company's diversified product portfolio across 13 products in 9 therapeutic categories enables it to cater to a broad spectrum of market needs, enhancing its competitive edge.

Ind-Swift Limited's key differentiators include its diversified product portfolio, with a focus on high-demand therapeutic categories such as Antihistamines & Allergy, Cardiovascular, and Antibiotics. The company's leadership in the Sulfasalazine market underscores its expertise in specific therapeutic areas. Additionally, Ind-Swift Limited's adherence to international quality standards, evidenced by certifications like WHO GMP and EU GMP, distinguishes it in the global market. The company's strategic geographic diversification further mitigates risks and positions it for sustained growth.

Ind-Swift Limited's current strategic direction focuses on the export of generic pharmaceutical formulations, with a strong emphasis on high-demand therapeutic segments. The company's adherence to international quality standards and its diversified geographic presence reflect a commitment to global expansion. Looking ahead, Ind-Swift Limited is well-positioned to leverage its strengths in generics and specialty pharmaceuticals to explore opportunities in biosimilars and Contract Development and Manufacturing Organizations (CDMO) services, aligning with industry trends and market demands.

Ind-Swift Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with an export value of $36.7 million USD across 1,476 shipments. The company's adherence to international quality standards, as evidenced by certifications like WHO GMP and EU GMP, indicates a commitment to product quality and safety. The absence of publicly available records of regulatory non-compliance further suggests reliability in its operations. These factors collectively position Ind-Swift Limited as a dependable supplier in the global pharmaceutical market.

Importers should verify the following certifications when considering Ind-Swift Limited as a supplier:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

• WHO GMP Certification: Verify the company's adherence to the World Health Organization's Good Manufacturing Practices, ensuring product quality and safety.

• EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practice certificates, facilitating market access in EU member countries.

• ISO Certification: Check for ISO certifications, such as ISO 9001-2008, indicating adherence to international quality management standards.

These